WHO gives a situation assessment of the MERS-CoV outbreak in Republic of Korea
3 June 2015 | By Victoria White
The outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) in the Republic of Korea continues to evolve, says WHO...
List view / Grid view
News
NICE recommends VARGATEF in combination with docetaxel as an option for patients with NSCLC of adenocarcinoma histology
3 June 2015 | By Victoria White
Boehringer Ingelheim’s VARGATEF in combination with docetaxel has been recommended for use within the National Health Service (NHS) in England and Wales...
Trabectedin shown to improve disease control in patients with advanced soft tissue sarcoma
3 June 2015 | By Victoria White
Janssen Research & Development has announced data from a Phase 3 study of trabectedin (YONDELIS) in patients with two common types of soft tissue sarcoma...
AbbVie presents Phase 2 results from study of veliparib in patients with NSCLC who are current smokers
3 June 2015 | By Victoria White
AbbVie has announced findings from a Phase 2 study of a veliparib regimen in patients with non-small cell lung cancer (NSCLC) who are current smokers...
Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression
3 June 2015 | By Victoria White
Results from an interim analysis of the Phase III ELOQUENT-2 trial of elotuzumab in combination with lenalidomide and dexamethasone have been announced...
FDA accepts sBLA for Keytruda in advanced non-small cell lung cancer, and grants priority review
3 June 2015 | By Victoria White
The FDA has accepted for review the sBLA for Merck’s anti-PD-1 therapy, Keytruda, for the treatment of patients with advanced non-small cell lung cancer...
FDA accepts sBLA for Opdivo+Yervoy regimen in patients with previously untreated advanced melanoma
2 June 2015 | By Victoria White
The FDA has accepted the supplemental Biologics License Application for Opdivo+Yervoy regimen in patients with previously untreated advanced melanoma...
Scancell provides update on Phase 1/2 clinical trial of SCIB1 in Stage III/IV melanoma
2 June 2015 | By Victoria White
Encouraging results have been announced from a Phase 1/2 trial of SCIB1, a DNA ImmunoBody being developed for the treatment of patients with melanoma...
Syrris launches novel quantum dot synthesis system
2 June 2015 | By kdm communications
Syrris, a world leader in chemistry product innovation, has launched the Atlas Nanoparticle System for the automated synthesis of quantum dots...
Urgent action needed to lessen the future impact of atrial fibrillation
2 June 2015 | By Victoria White
The Future of Anticoagulation Report highlights that urgent action is critical to lessening the potential impact of atrial fibrillation...
Asia-Pacific rheumatoid arthritis treatment market value will reach $7 billion by 2021
2 June 2015 | By Victoria White
The rheumatoid arthritis therapeutics market in the Asia-Pacific (APAC) region will expand in value from $5.6 billion in 2014 to an estimated $7 billion by 2021, at a moderate Compound Annual Growth Rate (CAGR) of 3.3%, according to business intelligence provider GBI Research.
NICE recommends aflibercept and dexamethasone as possible treatment options for diabetic macular oedema
2 June 2015 | By Victoria White
NICE has recommended aflibercept solution for injection and dexamethasone intravitreal implant as possible treatment options for diabetic macular oedema...
Amgen and Roche collaborate on cancer immunotherapy study with talimogene laherparepvec and atezolizumab
2 June 2015 | By Victoria White
Amgen and Roche are to collaborate on a study to evaluate talimogene laherparepvec in combination with atezolizumab in patients with cancer...
NICE rejects ovarian cancer drug olaparib over cost
2 June 2015 | By Victoria White
Draft guidance issued by NICE on the drug olaparib do not recommend its use for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
NICE issues final approval for Gazyvaro in chronic lymphocytic leukaemia
From today, clinicians in England and Wales will be able to prescribe Roche's Gazyvaro for eligible patients with chronic lymphocytic leukaemia (CLL) on the NHS.
